Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alo...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0060574&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727721745154048 |
|---|---|
| author | Tamara Kusay Jabbar Eva Calvo-Pinilla Francisco Mateos Simon Gubbins Abdelghani Bin-Tarif Katarzyna Bachanek-Bankowska Oya Alpar Javier Ortego Haru-Hisa Takamatsu Peter Paul Clement Mertens Javier Castillo-Olivares |
| author_facet | Tamara Kusay Jabbar Eva Calvo-Pinilla Francisco Mateos Simon Gubbins Abdelghani Bin-Tarif Katarzyna Bachanek-Bankowska Oya Alpar Javier Ortego Haru-Hisa Takamatsu Peter Paul Clement Mertens Javier Castillo-Olivares |
| author_sort | Tamara Kusay Jabbar |
| collection | DOAJ |
| description | The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alone or in combination using either a homologous prime boost vaccination regime (rMVA/rMVA) or a heterologous vaccination regime (DNA/rMVA). The DNA/rMVA or rMVA/rMVA prime-boost were administered at a three week interval and all of the animals that received VP2 generated neutralising antibodies. The vaccinated and non-vaccinated-control mice were subsequently challenged with a lethal dose of BTV-8. Mice vaccinated with VP7 alone were not protected. However, mice vaccinated with DNA/rMVA or rMVA/rMVA expressing VP2, VP5 and VP7 or VP2 alone were all protected. |
| format | Article |
| id | doaj-art-b28594ec741c4973b9fe8b77c82ca44f |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b28594ec741c4973b9fe8b77c82ca44f2025-08-20T03:09:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6057410.1371/journal.pone.0060574Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.Tamara Kusay JabbarEva Calvo-PinillaFrancisco MateosSimon GubbinsAbdelghani Bin-TarifKatarzyna Bachanek-BankowskaOya AlparJavier OrtegoHaru-Hisa TakamatsuPeter Paul Clement MertensJavier Castillo-OlivaresThe protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alone or in combination using either a homologous prime boost vaccination regime (rMVA/rMVA) or a heterologous vaccination regime (DNA/rMVA). The DNA/rMVA or rMVA/rMVA prime-boost were administered at a three week interval and all of the animals that received VP2 generated neutralising antibodies. The vaccinated and non-vaccinated-control mice were subsequently challenged with a lethal dose of BTV-8. Mice vaccinated with VP7 alone were not protected. However, mice vaccinated with DNA/rMVA or rMVA/rMVA expressing VP2, VP5 and VP7 or VP2 alone were all protected.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0060574&type=printable |
| spellingShingle | Tamara Kusay Jabbar Eva Calvo-Pinilla Francisco Mateos Simon Gubbins Abdelghani Bin-Tarif Katarzyna Bachanek-Bankowska Oya Alpar Javier Ortego Haru-Hisa Takamatsu Peter Paul Clement Mertens Javier Castillo-Olivares Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS ONE |
| title | Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. |
| title_full | Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. |
| title_fullStr | Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. |
| title_full_unstemmed | Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. |
| title_short | Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. |
| title_sort | protection of ifnar mice against bluetongue virus serotype 8 by heterologous dna rmva and homologous rmva rmva vaccination expressing outer capsid protein vp2 |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0060574&type=printable |
| work_keys_str_mv | AT tamarakusayjabbar protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT evacalvopinilla protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT franciscomateos protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT simongubbins protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT abdelghanibintarif protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT katarzynabachanekbankowska protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT oyaalpar protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT javierortego protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT haruhisatakamatsu protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT peterpaulclementmertens protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 AT javiercastilloolivares protectionofifnarmiceagainstbluetonguevirusserotype8byheterologousdnarmvaandhomologousrmvarmvavaccinationexpressingoutercapsidproteinvp2 |